Insider Analysis From Nishith Desai Associates: Learning and Unlearning from Section 3(d) Of The Indian Patents Act (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
By Milind Antani and Gowree Gokhale, Nishith Desai Associates, Mumbai, Indi
You may also be interested in...
Supreme Court Judge Recused From Glivec Patent Case In India
MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India
Supreme Court Judge Recused From Glivec Patent Case In India
MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India
Stage Set For India To Frame Compulsory Licensing Provisions As Contrasting Groups Make Their Case
The Department of Industrial Policy and Promotion is analyzing and interpreting comments on a contentious subject that has kept Indian and multinational drug firms bitterly divided for more than five years, while forcing the government into a dilemma over an acceptable policy.